TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06155643

Intervention type: DEVICE
Group type: OTHER
Intervention: Eko Sensora
Description: The exam involves placing the stethoscope in the aortic, pulmonic, tricuspid, and mitral areas for 15-30 seconds until a green light is displayed indicating that useful sound has been recorded. The recording is then uploaded by the device using wi-fi to the AI program for analysis. It does not carry patient identifiers. The device then indicates whether a clinically significant heart murmur was heard, and if so in which recording.
Study: NCT05587673

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: High dose steroid injected directly into the inflamed bowel segment(s) via its arterial blood supply.
Study: NCT05071859

Intervention type: OTHER
Intervention: Whole Genome Sequencing
Description: Saliva collection and request for banked blood and tumor samples for sequencing

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Study questionnaire will include modules that collect information on maternal reproductive history, exposure to known teratogens, medical history, and previous genetic testing.

Intervention type: OTHER
Intervention: Biospecimen collection
Description: Saliva collection and request for banked blood and tumor samples for sequencing and biomarker analysis

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Saliva collection and request for banked blood and tumor samples for biomarker analysis
Study: NCT04805944

Intervention type: DRUG
Intervention: Dolutegravir
Description: Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.

Intervention type: DRUG
Intervention: Bictegravir
Description: Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.

Intervention type: DRUG
Intervention: Dolutegravir
Description: Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.

Intervention type: DRUG
Intervention: Dolutegravir
Description: Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir

Intervention type: DRUG
Intervention: Bictegravir
Description: Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
Study: NCT05920915

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-interventional clinical research
Description: This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-interventional clinical research
Description: This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-interventional clinical research
Description: This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
Study: NCT06107504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: 2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
Study: NCT05829330

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient
Description: Outpatient Initiation of noninvasive mechanical ventilation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hospitalization
Description: Initiation of non-invasive mechanical ventilation during hospitalization
Study: NCT04989218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel combination of chemotherapy and immunotherapy
Description: This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
Study: NCT04889950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel C
Description: Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow
Description: LipiFlow
Study: NCT04592562

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Terumo Hydropearl® microspheres device
Description: Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch.
Study: NCT06397183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Strech with Traction (TSLR) Technique
Description: The Mulligan traction straight leg raise (TSLR) technique is a mobilization technique that can increase hamstring flexibility and range of motion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation Technique
Description: Post-Isometric Relaxation Technique is a Muscle Energy Technique which increases hamstring flexibility and range of motion.
Study: NCT06312124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Module
Description: Part 1 consists of an education module with premodule and postmodule assessment questionnaires.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Part 2 consists of incorporating opportunistic salpingectomy /OS into non-gynecologic surgery
Study: NCT06148948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862
Study: NCT06565338

Intervention type: DRUG
Intervention: Dexmedetomidine
Description: drug
Study: NCT04919681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretch exercises
Description: The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
Study: NCT06148948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1584862
Study: NCT06121284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
Study: NCT04550728

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ankle robot training group
Description: Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ankle robot training and functional electrical stimulation(FES) group
Description: Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
Study: NCT04560582

Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.
Study: NCT06051968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online hearing support for first-time hearing aid users
Description: Participants get hearing rehabilitation according to common practice and the online hearing support consists of five chapters that aim to give information, support, and advice to the new hearing aid users. The participants are assigned a new chapter between each visit at the clinic.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hearing rehabilitation according to common practice.
Description: Participants get hearing rehabilitation according to common practice.
Study: NCT06152575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab will be administered subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab will be administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally
Study: NCT05078021

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Bronchoscopy
Description: Bronchoscopy will be performed in all groups with endobronchial biopsies, brushings and bronchial washing performed.
Study: NCT05883319

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manuel therapy
Description: approaches will be applied for 3 days / week for 6 weeks.
Study: NCT06565338

Intervention type: DRUG
Intervention: Vitamin D3
Description: drug
Study: NCT05883319

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manuel therapy
Description: approaches will be applied for 3 days / week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: approaches will be applied for 3 days / week for 6 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: approaches will be applied for 3 days / week for 6 weeks.
Study: NCT05410535

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patients who continued UDCA 300mg medication
Description: patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients who continued UDCA 300mg medication
Description: patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients who continued UDCA 300mg medication
Description: patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patients who discontinued UDCA 300mg prescription
Description: patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients who discontinued UDCA 300mg prescription
Description: patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients who discontinued UDCA 300mg prescription
Description: patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
Study: NCT06429371

Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: Participants will undergo heat pain threshold, cold pain threshold, pressure pain threshold, temporal summation, and conditioned pain modulation to characterize pain sensitivity.
Study: NCT05019703

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study: NCT06429371

Intervention type: OTHER
Intervention: Pain-Related Psychological Factors
Description: Participants will complete psychological questionnaires to characterize these factors.
Study: NCT05390892

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Empagliflozin, dapagliflozin, or canagliflozin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 receptor agonist
Description: Dulaglutide, liraglutide, semaglutide
Study: NCT05296421

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uniformly-labeled [13C]glucose
Description: Given IV
Study: NCT05552586

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will receive capsules of the same size and color
Study: NCT06384807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-1510
Description: BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-1510
Description: BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-1510
Description: BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-1510
Description: BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks
Study: NCT06395142

Intervention type: OTHER
Intervention: pedal walking
Description: Pedal walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation. A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during pedal walking in stroke participants.

Intervention type: OTHER
Intervention: visual-deprivation walking
Description: visual-deprivation walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation.A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during visual-deprivation walking in stroke participants.
Study: NCT06152575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be administered subcutaneously or intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Carfilzomib will be administered intravenously
Study: NCT06268678

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase of the menstrual cycle
Description: Follicular or luteal phase

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase of the menstrual cycle
Description: Follicular or luteal phase
Study: NCT06059248

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the head in the sniffing position 
Description: Intubation was performed with the head in the  elevation  position
Study: NCT04925700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProDentis Lozenge
Description: 1-2 ProDentis Lozenges per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lozenge
Description: 1-2 Placebo Lozenges per day
Study: NCT04788017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziresovir
Description: Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Planned treatments are:~* Cohort 1: 300 mg of placebo~* Cohort 2: up to 600 mg of placebo~* Cohort 3: up to 900 mg of placebo
Study: NCT05087732

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STYLAGE® M Lidocaïne
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® M Lidocaïne
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STYLAGE® M
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® M
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
Study: NCT05911074

Intervention type: DIAGNOSTIC_TEST
Intervention: The Abbott Panbio™ COVID-19 Ag Rapid Test
Description: This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
Study: NCT05282199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INSPIRATORY MUSCLE TRAINING
Description: In the group of post-COVID-19 patients in which reduced endurance and inspiratory muscle power are identified, inspiratory muscle training (IMT) will be performed with a load equivalent to 50% of MIP (assessed weekly) for eight weeks.
Study: NCT06370702

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip Exercises
Description: Participants will firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
Study: NCT05495451

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting
Description: Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting
Description: Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.
Study: NCT04755868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients